Aberrations in the cross-talks among redox, nuclear factor-κB and Wnt/catenin pathway signaling underpin Myalgic Encephalomyelitis and chronic fatigue syndrome: a review and new hypothesis based on results of network, enrichment and annotation analyses.

Michael Maes, M.D., Ph.D. a,b,c, Marta Kubera, d Magdalena Kotańska, Ph.D e

a Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
b Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria
c IMPACT Strategic Research Center, Deakin University, Geelong, Australia
d Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Crakow, Poland
e Department of Pharmacological Screening, Jagiellonian University, Medical College, Medyczna 9, PL 30-688 Cracow, Poland

Corresponding author:

Prof. Dr. Michael Maes, M.D., Ph.D.

IMPACT Strategic Research Center

Barwon Health

Deakin University

Geelong, Vic

Australia

dr.michaelmaes@hotmail.com

https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao
Michael Maes: dr.michaelmaes@hotmail.com

Marta Kubera: kubera@if-pan.krakow.pl

Magdalena Kotańska: magda.dudek@uj.edu.pl
Abstract

There is evidence that chronic fatigue spectrum disorders (CFAS-D) including Myalgic Encephalomyelitis (ME), chronic fatigue syndrome (CFS) and chronic fatigue with physiosomatic symptoms including when due to comorbid medical disease are characterized by neuroimmune and neuro-oxidative biomarkers. The present study was performed to delineate the protein-protein interaction (PPI) network of CFAS-D and to discover the pathways, molecular patterns and domains enriched in their PPI network. We performed network, enrichment and annotation analysis using differentially expressed proteins and metabolics, which we established in CFAS-D patients. PPI network analysis revealed that the backbone of the highly connective CFAS-D network comprises NFkB1, CTNNB1, ALB, peroxides, NOS2, TNF, and IL6, and that the network comprises interconnected immune-oxidative-nitrosative and Wnt/catenin subnetworks. MultiOmics enrichment analysis shows that the CFAS-D network is highly significantly associated with cellular (antioxidant) detoxification, hydrogen peroxide metabolic process, peroxidase and oxidoreductase activity, IL10 anti-inflammatory signaling, and neurodegenerative, canonical Wnt, the catenin complex, cadherin domains, cell-cell junctions and TLR2/4 pathways; and the transcription factors NF-κB and RELA. The top-10 DOID annotations of the CFAS-D network include four intestinal, three immune system disorders, cancer and infectious disease. Custom GO term annotation analysis revealed that the CFAS-D network is associated with a response to a toxic substance, lipopolysaccharides, bacterium or virus. In conclusion, CFAS-D may be triggered by a variety of stimuli and their effects are mediated by aberrations in the cross-talks between redox, NF-κB, and Wnt/catenin signaling pathways leading to dysfunctions in multicellular organismal homeostatic processes.
Key words: chronic fatigue syndrome, Myalgic Encephalomyelitis, inflammation, neuro-immune, oxidative and nitrosative stress, antioxidants
Introduction

Contemporary research of chronic fatigue spectrum disorders (CFAS-D) including Myalgic Encephalomyelitis (ME), chronic fatigue syndrome (ME/CFS) and chronic fatigue (CF) and associated psychosomatic symptoms is plagued by a cacophony of controversies. These different approaches, sometimes even competing, comprise folk psychology (the culprit of CFAS-D is a psychological problem) and the medical approach (the culprit is one specific virus or different viruses or bacteria). The dominant view, especially in Europe, is that of the cognitive-behavioral and the biopsychosocial schools [1]. This view entails that CFAS-D, even when due to medical disease (e.g. cancer), are the consequence of psychosocial and biological factors and negative cognitions [1-4]. The Wessely model, for example, conceptualizes that the effects of a trigger factor, which may be a virus, are mediated by boom and bust activity and bedrest and the Vercoulen model considers that CFAS-D symptoms are aggravated by causal attributions and reduced physical activity [1]. Nevertheless, it appears that the label “biopsychosocial” is more window dressing than the actual approach because, in fact, folk psychology statements abounds in their publications as for example “it is in the mind”, “they think themselves ill” and “it is a disorder of perception whereby patients think those symptoms are the consequence of a virus” [review: 2]. Nevertheless, this folk psychology approach is embraced by the NHS, the Lancet and national health case system all over Europe (e.g., UK, France, Sweden, Benelux).

It is incomprehensible that expert committees make consensus diagnostic criteria of ME/CFS (including the 1994 International Research Case Definitions and the 2003 Canadian Consensus criteria), whereas, in fact, these new diagnostic classes were never validated, for example by using machine learning techniques, and there is no evidence that the case definitions have reliability and replicability validity [2,4,5]. One diagnostic criterion of both abovementioned
case definitions is that ME and CFS are not secondarily to medical disorders [6]. However, even CFS and ME, which are not secondary to any medical disorder, show a high comorbidity with symptoms of irritable bowel syndrome and depression [7], while CFAS-D symptoms are hallmarks of autoimmune, infectious, immune system and psychiatric disorders, including major depression and schizophrenia, and many more medical conditions [1,3,7-10]. CFAS-D symptoms are reflective manifestation of the symptomatome of for example COVID-19, chronic kidney disease with hemodialysis, schizophrenia, and rheumatoid arthritis [9,10-14], suggesting that CFAS-D symptoms are part of the core of these medical disorders and not the result of some “it is in the mind” process, if there would exist such a process.

It was not until 2010-2013, when Maes et al. [1,3,15] launched a new biomedical model, that more targeted medical research into CFAS-D began. These biomedical models of Maes et al. conceptualized CFAS-D as medical conditions whereby trigger factors such as immune activation, bacterial and viral infections, and a reduced protectome due to, for example, reduced antioxidant levels, may cause multiple adverse outcome pathways (AOPs) leading to the phenome of CFAS-D. The latter comprises CF symptoms, neurocognitive impairments, and depressive, sleep, gastrointestinal and autonomic symptoms, hyperesthesia and fibromyalgia-like symptoms, a flu-like malaise including post-exertional malaise [1,3,15]. Furthermore, we conceptualized psychosomatic symptoms accompanying CFAS-D as being the consequence of different AOPs and, therefore, re-labelled those symptoms as “physiosomatic” symptoms [16,17].

The key AOPs of CFAS-D (including those that are secondary to medical disorders such as COVID-19, chronic kidney disease, rheumatoid arthritis, schizophrenia, and major depression which we established in our studies between 2001-2021, are: a) oxidative and nitrosative stress (O&NS) as assessed by increased hydroperoxides (H$_2$O$_2$) and inducible nitric oxide (NOS)
synthase, and reduced antioxidant balances, including coenzyme Q10, zinc, dehydroepiandrosterone (DHEA), glutathione peroxidase (GPX)1, and albumin (ALB); b) a multitude of immune disorders as indicated by an altered expression of CD (cluster of differentiation) markers on peripheral blood mononuclear cells (CD3, CD8, CD19, CD38, CD69, and HLA-DR), increased levels of interleukin (IL)-1α and IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α and TNF receptors (TNFRs), soluble IL-1R antagonist (sIL-1RA), colony stimulating factor-2 (CSF2), high mobility group box protein 1 (HMGB1), neopterin, C-reactive protein (CRP), haptoglobin (HP), C–C motif chemokine ligand (CCL)2, CCL4, CCL11, cyclooxygenase-2 (PTGS2), soluble Toll Like Receptor (TLR)-4, lysozyme (LYZ), and elastase (ELANE); c) increased levels of nuclear-factor (NF)-κB, a transcriptional factor; d) changes in cell-cell-junction and Wnt pathway proteins including catenin-β (CTNNB1), claudin-5 (CLDN5), occludin (OCLN), Dickkopf Wnt Signaling Pathway Inhibitor 1 (DKK1), and R-spondin-1 (RSPO1), e) altered levels of endorphin-opioid molecules; and f) induction of the tryptophan catabolite (TRYCAT) pathway with increased levels some neurotoxic TRYCATs, including 3-OH-kynurenine.

In addition, we also discovered that ME/CFS is characterized by increased IgA/IgM responses to Gram-negative bacteria indicating increased bacterial or lipopolysaccharide translocation, and IgM-mediated autoimmune responses to a number of neoantigens including malondialdehyde (MDA), azelaic acid and nitrosylated proteins, indicating increased nistrosylation [18,19].

All in all, these findings show that multiple differentially expressed proteins (DEPs) and metabolic pathways are involved in the pathophysiology of CFAS-D. However, no research has delineated the protein-protein interaction (PPI) and metabolic-protein interactions (MPI) networks
of CFAS-D and the biological processes, molecular functions and complexes, cellular components, pathways, transcriptional regulatory relationships, protein domains and human disease annotations which are associated with the PPI and MPI networks of CFAS-D.

Hence, we have conducted network, enrichment and annotation analyses in order to delineate the hotspots in the CFAS-D network and the top functions and paths enriched in the networks. This is important because the most influential genes, metabolics, and pathways may constitute new drug targets to treat CFAS-D. Moreover, such analyses may disclose the putative trigger factors of the CFAS-D interactome and its associations with comorbid medical disorders. As such, these enrichment and annotation analyses may help to explain the strong comorbidity of CFAS-D with immune, infectious, and neuro-psychiatric disorders and the possible shared pathophysiological core which may underpin CFAS-D.

Methods

Selection of seed proteins and metabolic markers

“This study is a secondary data analysis on existing data using open, deidentified and non-coded data sets and, therefore, this is non-human subjects research which is not subject to Institutional Review Board approval” [20]. In case-control studies, we previously have identified metabolic pathways and differentially expressed proteins (DEPs) in CFAS-D including when due to comorbid medical disease. Almost all biomarkers included in this study were extracted from our studies on ME/CFS and CF-like symptoms with a duration > 6 months in comorbid disorders including major chronic kidney disease with hemodialysis, depression, schizophrenia, and rheumatoid arthritis (Electronic Supplementary File (ESF), 1, References). One study was performed on patients with CF-like symptoms due to acute COVID-19 infection. We were able to
include a) 42 DEPs, namely ACE2 (angiotensin converting enzyme 2), AGER (advanced glycosylation end-product specific receptor), AGRN (agrin), ALB, CCL2, CCL4, CCL11, CD3D, CD8A, CD19, CD38, CD69, HLA-DR, CKM (creatinine phosphokinase), CLDN5, CSF2, CRP, CTNNB1, DKK1, ELANE, GPX1, HbA1 (hemoglobin), HP, HMGB1, IL1A (interleukin-1α), IL1B (interleukin-1β), IL1RN (IL-1RA), IL6, IL10, LYZ, NFKB1 (NF-κB), NOS2, OCLN, OPRK1 (opioid receptor Kappa 1), OPRM1 (opioid receptor Mu 1), POMC (proopiomelanocortin as precursor of β-endorphins), PTGS2, RSPO1, TLR4, TNF (TNF-α), TNFRSF1A (TNFR60) and TNFRSF1B (TNFR80); and b) 12 metabolic KEGG (Kyoto Encyclopedia of Genes and Genomes; https://genome.jp/kegg/) pathways, namely C01290 (lactosylceramide), C02470 (xanthurenate), C10164 (picolinic acid), C03227 (3-OH-L-kynurenine, 3OHK), C11378 (coenzyme Q10), C00038 (zinc), C00070 (copper), C06428 (eicosapentaenoic acid; EPA), C00027 (hydrogen peroxides), C19440 (malondialdehyde, MDA), C004555 (DHEA), and C05926 (neopterin).

PPI network construction, and enrichment and annotation analyses.

The network, enrichment and annotation analysis were conducted as reviewed previously [20]. In brief, we constructed two network subtypes, the first was constructed using the abovementioned DEPs whereby the physical interactions between the DEPs were visualized using STRING version 11.0 (https://string-db.org) and Cytoscape (https://cytoscape.org). The second was constructed using OmicsNet (www.omicsnet.ca) using the abovementioned metabolites and examining the MPI based on KEGG reactions. Consequently, the genes interacting with the metabolics in the different subnetworks were used in STRING to
build a giant network based on our seed genes enlarged with the MPI-derived DEPs, which was, consequently, analyzed in OmicsNet to construct a composite network consisting of metabolites and DEPs first entering MPIs and then the PPIs (analyzed with IntAct Molecular Interaction Database: https://www.ebi.ac.uk/intact/) an with a targeted incorporation of TF-protein interactions (TFPI) (analyzed using TTRUST (www.grnpedia.org/ttrust)).

Network features were computed using STRING and the Cytoscape plugin Network Analyzer and comprise number of nodes, number of edges and expected number of edges, average node degree, network diameter and radius, characteristic path length, and network density and heterogeneity. The top hubs (high degree) and bottlenecks (high betweenness centrality) were computed and used to delineate the backbone of the network, i.e. the top7 hubs and the top-2 non-hub bottlenecks. We used Markov Clustering (MCL) employing STRING to discover communalities of interconnected nodes, which display similar attributes and/or functions.

We examined the different networks and MCL subnetworks for their enrichment scores and annotated terms and these analyses were also performed on the downregulate seed genes and the hotspots of the enlarged network. Enrichment/annotation analyses were performed using STRING, Enrichr (https://maayanlab.cloud/Enrichr/), OmicsNet, MetaScape (https://metascape.org), inBio Discover (https://inbio-discover.com), and the R package ClusterProfiler. Heatmaps were produced using Appyter and MetaScape. Functional enrichments were established using gene Ontology (GO) biological processes, GO molecular functions and GO cellular components, STRING local network clusters, KEGG pathways, Reactome pathways (the European Bio-Informatics Institute Pathway Database; https://reactome.org), PANTHER biological processes (PANTHER - Gene List Analysis (pantherdb.org), TTRUST transcriptional
regulatory relationships, InterPro domains (InterPro (ebi.ac.uk)), Wiki pathways (WikiPathways - WikiPathways), and DOID annotations of human diseases (Disease Ontology - Institute for Genome Sciences @ University of Maryland (disease-ontology.org)). We also performed Molecular Complex Detection (MCODE) (using Metascape) to delineate small molecular complexes.

Results

The DEP PPI network topography of CFS

**Figure 1** shows the first order protein network of CFAS-D. This network comprises 91 nodes and 938 edges, exceeding the expected number of edges (n=323) with a p-enrichment value of 1.0E-16. The network has an average local clustering coefficient of 0.683 and average node degree of 20.6, with a network diameter of 4, radius of 2, a characteristic path length = 1.978, network density = 0.229, and heterogeneity = 0.682. The top-7 hubs (highest degree) were in descending order of importance: TNF (degree=63), IL6 (61), IL1B (58), ALB (54), TLR4 (47), IL10 (47) and CTNNB1 (46). The top-two non-hub bottlenecks were: EGFR (0.066) and TLR2 (0.0188). EGFR and TLR were the top 5 and 9 in the bottleneck list (top 3 in descending order was ALB, CTNNB1 and TNF). The network of the seed proteins showed 42 nodes and 311 edges, thus, exceeding the expected number of edges (n=70) with a p-enrichment value of 1.0E-16. The network has an average local clustering coefficient of 0.74 and an average node degree of 14.8.

MCL cluster analysis (inflation parameter of 2) resulted in two protein subnetworks as shown in Figure 1. The first subnetwork contains predominantly immune genes, EGFR, ALB, AGER, HP, GPX1, CD19, etc., and the second subnetwork contains Wnt and cell-cell junction associated genes including CTNNB1, AGRN, RSPO1, and DKK1. The major connectors
(switches) of both subnetworks were CTNNB1 (belongs to subnetwork 2) and ALB and IL6 (nodes in subnetwork 1). CTNNB1 showed relevant interactions (confidence level > 0.4) with DKK1 and RSPO1 and with 11 subnetwork 1 seed genes (e.g. NFKB1, ALB, OCLN, TLR4, HMGB1). ALB showed significant interactions with 25 other subnetwork 1 genes, and with CTNNB1, AGRN and DKK1. IL6 showed interactions with CTNNB1, DKK1, and AGRN and 28 other subnetwork 1 seed nodes. In the first-order non-seed genes we found that EGFR was connected with 3 subnetwork 2 seed genes (GRN, CTNNB1, and DKK1) and with 19 seed genes in subnetwork 1.

**MultiOmics Analysis including the oxidative stress-associated metabolites.**

In order to construct a second giant network including proteins interconnecting with the metabolites, we entered the latter in OmicsNet analysis and examined the MPIs (using KEGG and IntAct and using only the first order MPIs). We found 5 subnetworks: one centered around hydroperoxides (46 nodes), another around EPA (6 nodes), 6 around 3OHK, 4 around NO, and 3 around DHEA (albeit some overlapping). The 59 nodes coupled with the nodes from the first network (see Figure 2) were consequently examined using STRING and Network Analyzer. **Figure 2** shows the network based on this combination of DEPs. This network comprises 147 nodes and 1407 edges, exceeding the expected number of edges (n=413) with a p-enrichment value of 1.0E-16. The network has an average local clustering coefficient of 0.624 and average node degree of 19.1, with a network diameter of 5, radius of 3, characteristic path length = 2.278, network density = 0.131, and heterogeneity = 0.799. The top-7 hubs (highest degree) were in descending order of importance: TNF (degree=82), IL6 (79), ALB (75), IL1B (74), CAT (59; catalase), IL10 (57) and TLR4 (57). The top-5 bottlenecks were CAT (0.1534), ALB (0.1212), CTNNB1 (0.0918), TNF (0.08867, and IL-6 (0.06755). The first non-hub bottlenecks were EGFR (0.04909) and NOS2 (0.04572).
Figure 2 shows the results of MCL cluster analysis (inflation parameter of 1.7) displaying two significant protein subnetworks, a first comprising immune and nitro-oxidative stress genes (see Figure 6; this cluster is now re-named the immune-inflammatory, oxidative and nitrosative cluster, IO&NS), and a second Wnt/catenin cluster. There were also some communities with only few nodes, for example one centered around KYNA (kynureninase) and KMO (kynurenine 3-monooxygenase).

Figure 3 shows the results of OmicsNet analysis which included all IO&NS/Wnt genes of the network presented in Figure 2 with integration of the metabolics and NFKB (as transcriptional factor). This network was constructed using three interaction types, namely MPI (first rank), PPI (second rank) and TFPI (third rank) and included 574 nodes and 694 edges. The top hubs (including non-seeds) in this network were NOS2 (177), NOS3 (63), SOD2 (57), PRDX6 (47), peroxides (45), SOD1 (41), KYNU (32), and NFKB1 (29). We also examined the hubs of the network built with PPIs entered in first order and MPI in second order (2593 nodes and 4063) and found that the top-3 hubs were in descending order of importance: NFKB1 (307), CTNNB1 (153), and ALB (152). As such, the common backbone of the different networks (top-3 of each network) in our study consists of NFKB1, CTNNB1, ALB, peroxides, NOS2, TNF, and IL6.

Table 1 shows the results of PANTHER functional explorer analyses. The top PANTHER molecular functions which were enriched in this network revolved around protein binding, peroxidase and oxidoreductase activity; and the top PANTHER cellular components were the cytosol, protein-containing complex, cytoplasm and the nucleus.

*Enrichment and annotation analysis in all IO&NS/Wnt genes of CFAS-D.*
Table 2 displays the results of MCODE analysis using KEGG, WikiPaths, GO biological and molecular, REACTOME and PANTHER performed on the IO&NS/Wnt genes. We found five significant molecular complexes, the first represents cytokine/IL10 signaling and a response to LPS; the second comprises cellular oxidant detoxification and response to a toxic substance; the third amine oxidase reactions, hydrogen peroxide metabolic process and degradation of beta catenin; the fourth peroxisomal protein import and a carboxylic acid catabolic response; and the fifth was the same as MCODE2 in Table 2.

Table 3 shows the most important GO biological processes, InterPro domains, and KEGG pathways enriched in the IO&NS/Wnt network. GO biological process enrichment analyses showed that this network was significantly associated with oxidoreductase, antioxidant and peroxidase activity and beta-catenin binding. InterPro enrichment analyses showed that haem peroxidase and glutathione peroxidase were the top terms. KEGG path analysis showed that the network was highly associated with the Wnt signaling and NF-κB pathway, tryptophan metabolism and illnesses including tuberculosis and Chagas disease.

Figure 4 shows the enriched ontology clusters (using MetaScape) in the network with cellular oxidant detoxification, IL10 signaling and a response to LPS as the top terms. Figure 5 shows a heatmap (made using Enrichr and Appyter) with the top KEGG pathways that were over-represented in the IO&NS/Wnt network, namely pathways of neurodegeneration, Wnt and NF-κB signaling and peroxisome. Figure 6 shows a heatmap with the PANTHER 2016 pathways which were over-represented in the network, namely Wnt, apoptosis, TLR and cadherin pathways and the Alzheimer disease presenilin pathway. TTRUST analysis showed that NF-κB (pFDR=6.58E-23) and RELA (pFDR=8.691E-21) were the most important transcriptional factors of the network followed at a large distance by SP1 (pFDR=7.079E-13).
Table 4 shows the top-10 DOID annotations of an extended IO&NS/Wnt network (inBio Discover) including four intestinal disorders as the top 4 annotations, immune disorders and cancer.

Electronic Supplementary File (ESF) 1 and ESF 2 show the results of enrichment and annotation analysis performed on the DEPs (or selected DEPs) presented in Figure 1.

Discussion

The networks and subnetworks of CFAS-D

The first major finding of this study is that the PPI network of the DEPs and metabolics of CFAS-D show high connectivity and comprises two subnetworks, a first centered around IO&NS genes and a second around Wnt/catenin genes. The backbone of the master network comprises DEPs/metabolics including NFKB1, CTNNB1, ALB, peroxides, NOS2, TNF, and IL6, while in the giant network many redox-related enzymes were predicted to be hubs, including NOS3 (endothelial NO synthase producing NO relaxing smooth muscle relaxation), SOD2 (mitochondrial superoxide dismutase 2) and PRDX6 (peroxiredoxin 6; catalyzes the reduction of hydrogen peroxides). It is important to note that without the delineation of the MPIs, one would have concluded that especially pro-inflammatory cytokine genes are the dominant forces in this network, whereas, in fact, the IO&NS subnetwork is more dominated by redox genes, NF-κB and IL-10.

CTNNB1, which belongs to the Wnt subnetwork was another hotspot and additionally showed many interactions with genes in both subnetworks indicating that this gene is a relevant switch linking both subnetworks. Other relevant switches belonging to the immune subnetwork were ALB and IL6 which showed many interactions with cluster 1 genes, but also with CTNNB1,
DKK1 and AGRN. Hotspots and switches are considered to be new drugs targets because they govern and control the network and/or link the subnetworks [20]. All in all, we may conclude that dysfunctions in the IO&NS and Wnt subnetworks underpin the pathophysiology of CFAS-D.

**Terms over-represented in the IO&NS MultiOmics subnetwork**

The second major finding of this study is that the top relevant functions and pathways in the first network revolve primarily around redox mechanisms, namely cellular oxidant detoxification (and thus cellular detoxification and a cellular response to toxic substance), the hydrogen peroxide metabolic process, antioxidant activity, amine oxidase reactions, oxidoreductase activity, peroxidase activity, and haem and glutathione peroxidase. These findings indicate that increased oxidative stress (hydrogen peroxides) probably as a response to a toxic substance coupled with reduced antioxidant defenses (peroxidase, oxidase, oxidoreductase, ALB) are the major pathways in CFAS-D. Indeed, many of the seed DEPs and metabolics show antioxidant properties including ALB, GPX1, HP, CoQ10, DHEA, zinc and EPA, and pro-oxidant properties including NFKB1, NOS2, PTGS2, and hydroperoxides. Moreover, the giant network based on seed DEPs and MPI-derived genes indicates that many redox genes are expected to participate in the CFAS-D network, including CAT, GPX2-9, SOD1, SOD2, LPO, LOX, MPO, NOS1, NOS3, and PRDX6.

Such findings agree with the evidence that CFAS-D is characterized by reduced antioxidant defenses, and oxidative damage to lipids, proteins, DNA and mitochondria as reviewed in [1,3,7,15]. Such damage in ME/CFS is accompanied by formation of immunogenic oxidative modified neoeptopes which in turn may cause an IgM-mediated immune response against neoeptopes like malondialdehyde and azelaic acid [18]. The participation of NOS2 in the CFAS-
D network is in agreement with our reports that ME/CFS is accompanied by increased nitrosative stress, which is a consequence of increased NO and superoxide production resulting in hypernitrosylation [18]. In addition, also more recent papers indicate that increased nitro-oxidative stress and reduced antioxidant defenses contribute to idiopathic chronic fatigue, including increased reactive oxygen species, malondialdehyde, and F2-isoprotan, and lowered catalase and glutathione levels [21]. In patients with CFAS-D, baseline thiobarbituric acid–reactive substances (TBARS, an indicant of lipid peroxidation) are associated with exercise-induced pain [22]. A recent review describes how oxidative stress may cause membranopathies, channelopathies and mitochondrial dysfunctions which in turn may interfere with intracellular energy processes and imbalances in signal conversion system [23]. There are many reports showing that antioxidants may improve CFAS-D in animal models, including carvedilol, melatonin, Withania somnifera, quercetin and Hypericum perforatum L [24], curcumin [25], Sarcodon imbricatus [26] and many more.

The results of our network and enrichment analyses show that NFKB1 was not only one of the most important hotspots in the CFAS-D network, but also that NF-κB (p50-p52 unit) and RELA (NF-κB p65 unit or transcription factor p65) were the most important transcription factors controlling the network and that the NF-κB signaling pathway was one of the most important paths enriched in the network. NF-κB is a major transcriptional factor involved in the response to a vast array of stimuli including bacterial or viral antigens, cytokines, free radicals, oxidized epitopes, and glutamate, and is a transcriptional inducer of many genes including cellular adhesion molecules, pro-inflammatory cytokines, chemokines, and growth, apoptosis and coagulation factors, and antioxidants and pro-oxidants [27-29]. RELA is involved in the activation of NF-κB and stimulates NF-κB translocation to the nucleoplasm and by forming a RELA-NF-κB complex.
activates target gene expression [30]. NF-κB p50, which is associated with RELA, and NF-κB p52 are major components of the canonical and noncanonical NF-κB signaling pathways which both lead to target gene activation [29]. Both transcription factors are known to regulate different pathways that we observed to participate in the network including the MAPK pathway [31] and ROS and Wnt/catenin pathways.

There are many intersections between reactive oxygen species (ROS) and NF-κB signaling. Indeed, ROS may modulate the NF-κB response leading to transcriptional activation of NF-κB-target antioxidant genes (e.g. SOD, HO1, GPX1, TRX1 and TRX2), which reduce ROS production, thereby promoting cell survival [29], and NF-κB-target pro-ROS genes including NOX2, COX2, and NOS2 [29,32]. It should be stressed that the effects of ROS on NF-κB are more than complex with stimulatory effects in the cytoplasm and inhibitory effects in the nucleus [33], while ROS may also oxidize NF-κB p50 leading to decreased DNA binding capacity [34].

All in all, the results of our network and enrichment analysis and Maes et al. [35,36] indicate that the complex cross-talks between NF-κB and ROS signaling are involved in the pathophysiology of CFAS-D. Moreover, recent studies show that increased NF-κB expression may be associated with central fatigue by modulating central nervous system genes and regulating immune-inflammatory processes, synaptic plasticity, and memory and exerting neurotoxic effects [35-37].

Our MCODE analysis revealed that the IL-10 anti-inflammatory signaling pathway, regulation of cytokine production, signaling by interleukins and a response to LPS was a relevant molecular complex in the IO&NS subnetwork of CFAS-D. These findings agree with those of our previous studies showing increased IgA/IgM response to LPS of 6 different Gram-negative bacteria in CFAS-D, indicating increased bacterial translocation [19]. Previously, we have argued
that part of the effects of translocated LPS on cytokine production could be explained by induction of the TLR signaling pathway which also signals to NF-κB which in turn may activate cytokine genes [38,39].

Our enrichment analysis also showed an association between the IO&NS subnetwork and the lactoferrin (LTF) danger signal response pathway. LTF, an iron-binding glycoprotein, activates NF-κB via the TLR2/4 complexes and additionally RAGE and TREM-1 receptors [40]. LTF functions as a first line defense against injuries, either pathogenic or non-pathogenic and controls cell homeostasis [40]. Furthermore, LTF sequesters ROS (thereby attenuating tissue damage due to excessive IO&NS) and maintains intestinal integrity during endotoxemia [40]. Our enrichment analysis shows that the pro-inflammatory TNF-related weak inducer of apoptosis (TWEAK) signaling pathway is another possible link between tissue injury and upregulation of NFKB1-associated DEPs/genes by activating the NF-κB pathways [41].

The NF-κB signaling pathway not only regulates the transcription of pro-inflammatory genes including IFNG, IL1 and TNF, but also IL10, which has negative immune-regulatory effects, which protect against an overzealous inflammatory response [42]. IL10 has negative immune-regulatory activities by inhibiting the production of M1 macrophage and T helper (Th)-1 cytokines, dendritic cells stimulating CD4+ T cells, and Th-2 responses, and attenuates CD8+, M1 macrophage, Th-1 and Th-2 associated immunopathology [43,44]. It is important to note that our enrichment analysis stresses the importance of anti-inflammatory IL10 signaling as a response to LPS and regulation of cytokine signaling, suggesting that a predominant IL10 phenotype may occur in CFAS-D. Presuming that the latter are frequently triggered by a low/moderate pathogen (or LPS) virulence [1], we may expect that IL10 suppresses the ongoing immune response thereby contributing to long-term escape of pathogens from immune control and causing persistent or
recurrent infections [1, 43]. Therefore, immunosuppression which is another hallmark of CFAS-D may not only be explained by T cell exhaustion through increased pro-inflammatory cytokine production [45] but also by increased IL10.

Finally, our network and enrichment analyses showed that the TRYCAT pathway may be involved in CFAS-D, although it is not a key component but rather a spin-off of the IO&NS response. Previously, it was reported that this pathway is highly strongly associated with somatization disorder, a psychiatric disease accompanied by physiosomatic symptoms but not necessarily by fatigue [46]. The TRYCAT pathway acts as a redox-regulator and is one of the major antioxidant systems, although some TRYCATs have pro-oxidant and neurotoxic activities [47]. Thus 3OHK, one of the metabolics in our MPI network, is one of the neurotoxic TRYCATS produced during activation of this pathway as a consequence of IO&NS activation. KYNU (kynurenine hydroxylase) is as IDO an oxygen-consuming enzyme which catabolizes kynurenine into 3OHK (STRING).

Terms over-represented in the Wnt MultiOmics subnetwork

Our enrichment analyses revealed that the CFAS-D network was highly significantly associated with two major interrelated functions/pathways/domains namely the canonical Wnt/β-catenin pathway, T-cell factor (TCF) dependent signaling in response to Wnt, degradation of β-catenin by the destruction complex, the catenin complex and DIX domain, and adherens junctions, cadherin prodomain, and cell-cell junctions. The DIX domains and axin, GSK-3 and Dishevelled (Dvl) are key players in the β-catenin destruction complex thereby determining the interaction of β-catenin with the transcription factor TCF and, thus, the expression of the Wnt target genes [48].
The β-catenin/E-cadherin complex is the key component of adherens junctions (AJs), which stabilizes cell-cell junctions, provides cell-cell adhesion and bind catenin with the actin cytoskeleton [9,49]. Moreover, aberrations in the AJs lead to a breakdown of the tight junctions (TJs), another component of the paracellular route [50]. β-catenin and occludin are key factors in both the AJs and TJs (paracellular pathway) including those of the blood-brain barrier (BBB) and gut barriers, whereas claudin-5 is more specific to the BBB and E-cadherin to the gut barrier [9].

As a consequence, dysfunctions in AJs and TJs may cause aberrations in cell-cell adhesion and the actin cytoskeleton [51]. Furthermore, degradation of the E-cadherin-β-catenin complexes may cause aberrations in intracellular signaling, the actin cytoskeleton and the Wnt/β-catenin signaling pathway, a key component in cell homeostasis [52]. Previously, we reported that increased levels of zonulin (prehaptoglobin-2) are strongly associated with CFAS-D in schizophrenia and explain, at least in part, the aberrations in TJs and AJs and consequent breakdown in the paracellular route [9]. It should be added that aberrations in the paracellular route of the gut barrier are associated with increased bacterial or LPS translocation (leaky gut) and thus activation of the IO&NS pathways [9]. Moreover, increased ROS and NO production and pro-inflammatory pathways (TNF, IL6, IFNG) may damage the epithelial and endothelial TJs [53]. Furthermore, hydrogen peroxides may redistribute β-catenin and E-cadherin from the paracellular route into the cell thereby affecting the TJs and deplete occludin and damage the cytoskeleton as well [53]. It should be added that virulence factors of many pathogenic bacteria may exploit the Wnt/catenin pathway to alter the anti-bacterial immune response, including Pseudomonas aeruginosa, one of the bacteria involved in CFAS-D [19,54].

Importantly, our MCODE analysis revealed another highly significant molecular complex in the CFAS-D network comprising the hydrogen peroxide metabolic process, amine oxidase
reactions and the β-catenin degradation pathway, indicating that interactions between those factors are involved. Importantly, dysregulated Wnt/catenin signaling may cause oxidative stress in pregnant mice with CFS [55]. Nucleoredoxin (NRX), a thioredoxin-like protein, strongly inhibits Wnt/catenin binding and the expression of early genes, whereas H$_2$O$_2$ treatment stabilizes β-catenin and increases expression of Wnt genes [56]. Increased ROS promotes intrinsic apoptosis, and the consequent caspase 3 expression inhibits Wnt signaling in association with cleavage of E-cadherin [57]. H$_2$O$_2$ not only inhibits Wnt/b-catenin signaling but may also increase Wnt/catenin signaling [58]. In fact, peroxides have a biphasic effect on Wnt signaling with an increase 20 minutes after activation and reduced signaling some hours later [57]. Finally, β-catenin is a key regulator of the homeostatic cell response, which helps to repair the damage due to nitro-oxidative stress [59].

Furthermore, the NF-κB and Wnt pathways shows multiple cross-talks and negatively or positively regulate each other, thereby forming a mutual regulatory network [60]. Wnt modulates the production of inflammatory cytokines and NF-κK signaling and bridges innate and adaptive immune pathways [61]. On the other hand, increased levels of IL-6 and TNF-α may maintain increased Wnt signaling associated with low β-catenin, Dishevelled and axin levels [62]. It should be stressed that our network analysis showed that the key seed DEPs of both IO&NS (NFKB1) and Wnt (CTNBB1) pathways have significant physical interactions based on co-expression, experimental and biochemical data (STRING) thereby also functioning as an anchor linking the IO&NS and Wnt subnetworks. All in all, it appears that the pathophysiology of CFAS-D may be characterized by aberrations in the intertwined cross-talks between ROS, NF-κB and Wnt/catenin signaling.
Previously, we have explained how IO&NS and NF-κB and their associated pathways may explain the central and peripheral symptoms of CFAS-D [3,15,16,23,36,63]. The current study shows that alterations in the Wnt pathway may contribute to these symptoms because this pathway regulates the homeostasis in self-renewing tissues and has additionally organ-specific effects. For example, the Wnt/catenin pathway is involved in BBB integrity, synapse assembly, synapse functions, synaptic plasticity, neurogenesis, white matter lesion remyelination, dopamine neuron neuronal survival protection and regeneration, whereas aberrations in the Wnt/catenin pathway are associated with synaptic loss, BBB breakdown and neurodegenerative disease including Alzheimer’s and Parkinson’s disease [64-68].

The Wnt/catenin pathway is also involved in a) pain and neuropathic pain with Wnt inhibition improving pain [67,70]; b) skeletal muscle dynamics, the neuromuscular synapse, and musculoskeletal functions including the electrophysiologic properties of muscle cells [71,72]; c) intestinal functions including epithelial homeostasis and integrity, the physiological proliferation of the transit-amplifying cells and differentiation of Paneth, goblet, and enteroendocrine cells, and the maintenance of mucosa and barrier functions [73-76]. The Wnt/catenin pathway also plays a key role in autoimmunity as observed in rheumatoid arthritis [77,78] and in the response to bacterial infections and inflammation [79,80].

Conclusions

Figure 8 summarizes the pathways and molecular complexes or functions that accompany CFAS-D. Aberration in the cross-talks among redox, NF-κB, and Wnt signaling may be key pathways, which are associated with dysfunctions in multicellular organismal homeostatic processes including in cell-junction organization. Disorders in the intertwined interactions between
these systems may explain the broad spectrum of organs and dysfunctions that participate in CFAS-D (brain, musculoskeletal system, immune system, gastro-intestinal system). An important spin-off is increased IL10 production, which may contribute to immunosuppression and recurrent or protracted infections, and also increased TRYCAT production may aggravate the neurotoxic effects of oxidative stress. Increased translocation of Gram-negative bacteria with increased LPS load is probably a major trigger factor but also other bacterial infections, toxoplasmosis, viral infections (e.g. cytomegalovirus), cancer, and gastro-intestinal, autoimmune, immune-inflammatory, neuroinflammatory and neurodegenerative disorders appear to be associated with those pathways via activation of TLR/LTF/TWEAK signaling.

Future research should scrutinize the specific role of the NF-κB, ROS and Wnt axis in CFAS-D. The cross-talks between these three pathways may also constitute new drug targets to treat CFAS-D. Given that the Wnt pathway shows many complex, negative and positive feedback loops interacting with redox systems and NK-κB signaling, manipulations of Wnt signaling and β-catenin (despite being a hub and master switch) appears to be very challenging. It may be more promising to simultaneously target the crosstalk among redox and NF-κB pathways. New knowledge on the precise aberrations in the Wnt pathway in association with ROS and NF-κB signaling may lead to even more effective treatments by specifically targeting β-catenin, the β-catenin destruction complex or the TCF transcription factor.

Our new model shows that disorders in cross-talks among these three key pathways mediate the effects of a variety of trigger factors in the onset of CFAS-D. These findings also support the theory that once CFAS-D is present the abovementioned pathways may increase morbidity and even mortality of IO&NS-associated medical disorders through the detrimental effects of disorders in redox, NF-κB and Wnt axis [81,82]. The model also explains that the acute
phase of inflammatory conditions may lead to CFAS-D via disorders in this axis, oxidative damage and the neurotoxic effects of LPS, pro-inflammatory cytokines and TRYCATs. Since most biomarkers included in this study were extracted from studies on ME/CFS and CF-like symptoms in comorbid disorders with duration > 6 months, we may conclude that after resolution of acute inflammation, CAFS-D symptoms are maintained by continued aberrations in the redox, NF-κB, and Wnt axis, increased IL-10 production and increasing oxidative damage including secondary autoimmune responses and nitrosylation.

Funding statement

There was no specific support for this specific study.

Conflict of interest

The authors have no conflict of interest with any commercial or other association in connection with the submitted article.

Author’s contributions.

All the contributing authors have participated in the manuscript. MM designed the study and performed the network, enrichment and annotation analyses. All authors contributed to interpretation of the data and writing of the manuscript.

Compliance with ethical standards.

The study was conducted according to international ethics and privacy laws.
IRB statement.

This study is a secondary data analysis on existing data using open, deidentified and non-coded data sets and, therefore, this is non-human subjects research, which is not subject to IRB approval.

References.

1. Maes M, Twisk FN. Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med. 2010 Jun 15;8:35. doi: 10.1186/1741-7015-8-35. PMID: 20550693; PMCID: PMC2901228.

2. Morris G, Maes M. Case definitions and diagnostic criteria for Myalgic Encephalomyelitis and Chronic fatigue Syndrome: from clinical-consensus to evidence-based case definitions. Neuro Endocrinol Lett. 2013;34(3):185-99. PMID: 23685416.

3. Maes M. Inflammatory and oxidative and nitrosative stress cascades as new drug targets in myalgic encephalomyelitis and chronic fatigue syndrome. Mod Trends Pharmacopsychiatry. 2013;28:162-74. doi: 10.1159/000343982. Epub 2013 Feb 27. PMID: 25224898.

4. Maes M, Anderson G, Morris G, Berk M. Diagnosis of myalgic encephalomyelitis: where are we now? Expert Opin Med Diagn. 2013 May;7(3):221-5. doi: 10.1517/17530059.2013.776039. Epub 2013 Feb 27. PMID: 23480562.
5. Maes M, Rodriguez LA, Morris G. Is a diagnostic blood test for chronic fatigue syndrome on the horizon? Expert Rev Mol Diagn. 2019 Dec;19(12):1049-1051. doi: 10.1080/14737159.2020.1681976. Epub 2019 Oct 18. PMID: 31617771.

6. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisnik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011 Oct;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x. Epub 2011 Aug 22. Erratum in: J Intern Med. 2017 Oct;282(4):353. PMID: 21777306; PMCID: PMC3427890.

7. Maes M, Kubera M, Stoyanova K, Leunis JC. The reification of the clinical diagnosis of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) as an immune and oxidative stress disorder: construction of a data-driven nomothetic network and exposure of ME/CFS subgroups. Curr Top Med Chem. 2021 Jul 27. doi: 10.2174/1568026621666210727170147. Epub ahead of print. PMID: 34315375.

8. Maes M. An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):784-94. doi: 10.1016/j.pnpbp.2010.06.023. Epub 2010 Jul 4. PMID: 20609377.
9. Maes M, Andrés-Rodríguez L, Vojdani A, Sirivichayakul S, Barbosa D, Kanchanatawan B. In Schizophrenia, Chronic Fatigue Syndrome- and Fibromyalgia-Like Symptoms are Driven by Breakdown of the Paracellular Pathway with Increased Zonulin and Immune Activation-Associated Neurotoxicity. *Preprints* 2021, 2021050182 (doi: 10.20944/preprints202105.0182.v1).

10. Castro-Marrero J, Faro M, Aliste L, Sáez-Francàs N, Calvo N, Martínez-Martínez A, de Sevilla TF, Alegre J. Comorbidity in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Nationwide Population-Based Cohort Study. *Psychosomatics*. 2017 Sep-Oct;58(5):533-543. doi: 10.1016/j.psym.2017.04.010. Epub 2017 Apr 21. PMID: 28596045.

11. Mousa RF, Al-Hakeim HK, Alhaideri A, Maes M. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenotype of schizophrenia: neuro-immune and opioid system correlates. *Metab Brain Dis*. 2021 Jan;36(1):169-183. doi: 10.1007/s11011-020-00619-x. Epub 2020 Sep 23. PMID: 32965599.

12. Al-Jassas, H.; Al-Hakeim, H.; Maes, M. Intersections between Pneumonia, Lowered Oxygen Saturation Percentage and Immune Activation Mediate Depression, Anxiety and Chronic Fatigue Syndrome-like Symptoms due to COVID-19: A Nomothetic Network Approach. *Preprints* 2021, 2021060362 (doi: 10.20944/preprints202106.0362.v1).

13. Halah Nori Asad, Hussein Kadhem Al-Hakeim, Shatha Rouf Moustafa, Michael Maes. A causal-pathway phenotype of chronic fatigue syndrome due to hemodialysis. RG, Preprint.
14. Al-Hakeim HK, Al-Issa AAR, Maes M. Serum agrin and talin are increased in major depression while agrin and creatine phosphokinase are associated with chronic fatigue and fibromyalgia symptoms in depression. Metab Brain Dis. 2020 Jan;35(1):225-235. doi: 10.1007/s11011-019-00506-0. Epub 2019 Nov 16. PMID: 31734845.

15. Morris G, Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013 Sep 17;11:205. doi: 10.1186/1741-7015-11-205. PMID: 24229326; PMCID: PMC3847236.

16. Anderson G, Berk M, Maes M. Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand. 2014 Feb;129(2):83-97. doi: 10.1111/acps.12182. Epub 2013 Aug 17. PMID: 23952563.

17. Anderson G, Maes M, Berk M. Biological underpinnings of the commonalities in depression, somatization, and Chronic Fatigue Syndrome. Med Hypotheses. 2012 Jun;78(6):752-6. doi: 10.1016/j.mehy.2012.02.023. Epub 2012 Mar 23. PMID: 22445460.

18. Maes M, Mihaylova I, Leunis JC. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett. 2006 Oct;27(5):615-21. PMID: 17159817.
19. Maes M, Mihaylova I, Leunis JC. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J Affect Disord. 2007 Apr;99(1-3):237-40. doi: 10.1016/j.jad.2006.08.021. Epub 2006 Sep 27. PMID: 17007934.

20. Maes, M.; Plaimas, K.; Suratanee, A.; Noto, C.; Kanchanatawan, B. The Protein-Protein Interaction Network of First Episode Psychosis and Schizophrenia Reveals Possible Trigger Factors and New Drug Targets among Intracellular Signal Transduction Pathways and Neurotoxicity Processes. Preprints 2021, 2021070596 (doi: 10.20944/preprints202107.0596.v1).

21. Lee JS, Kim HG, Lee DS, Son CG. Oxidative Stress is a Convincing Contributor to Idiopathic Chronic Fatigue. Sci Rep. 2018 Aug 27;8(1):12890. doi: 10.1038/s41598-018-31270-3. PMID: 30150620; PMCID: PMC6110864.

22. Polli A, Van Oosterwijck J, Nijs J, Marusic U, De Wandele I, Paul L, Meeus M, Moorkens G, Lambrecht L, Ickmans K. Relationship Between Exercise-induced Oxidative Stress Changes and Parasympathetic Activity in Chronic Fatigue Syndrome: An Observational Study in Patients and Healthy Subjects. Clin Ther. 2019 Apr;41(4):641-655. doi: 10.1016/j.clinthera.2018.12.012. Epub 2019 Jan 18. PMID: 30665828.

23. Bjørklund G, Dadar M, Pivina L, Doşa MD, Semenova Y, Maes M. Environmental, Neuro-immune, and Neuro-oxidative Stress Interactions in Chronic Fatigue Syndrome. Mol Neurobiol.
24. Singh A, Naidu PS, Gupta S, Kulkarni SK. Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J Med Food. 2002 Winter;5(4):211-20. doi: 10.1089/109662002763003366. PMID: 12639396.

25. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K. Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology. 2009;214(1):33-9. doi: 10.1016/j.imbio.2008.04.003. Epub 2008 Jun 17. PMID: 19159825.

26. Wang X, Qu Y, Zhang Y, Li S, Sun Y, Chen Z, Teng L, Wang D. Antifatigue Potential Activity of Sarcodon imbricatus in Acute Excise-Treated and Chronic Fatigue Syndrome in Mice via Regulation of Nrf2-Mediated Oxidative Stress. Oxid Med Cell Longev. 2018 Jun 28;2018:9140896. doi: 10.1155/2018/9140896. PMID: 30050662; PMCID: PMC6046126.

27. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006 Oct 30;25(51):6680-4. doi: 10.1038/sj.onc.1209954. PMID: 17072321.

28. Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol. 2006;6(2):111-30. doi: 10.1385/ct:6:2:111. PMID: 17303919.
29. Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells. 2010 Jul;30(1):1-12. doi: 10.1007/s10059-010-0105-0. Epub 2010 Jul 14. PMID: 20652490; PMCID: PMC6608586.

30. UniProtB. UniProtKB - Q04206 (TF65_HUMAN). RELA - Transcription factor p65 - Homo sapiens (Human) - RELA gene & protein (uniprot.org). As assessed 23-7-2021.

31. Ma S, Santhosh D, Kumar T P, Huang Z. A Brain-Region-Specific Neural Pathway Regulating Germinal Matrix Angiogenesis. Dev Cell. 2017 May 22;41(4):366-381.e4. doi: 10.1016/j.devcel.2017.04.014. PMID: 28535372; PMCID: PMC5492999.

32. Napolitano M, Zei D, Centonze D, Palermo R, Bernardi G, Vacca A, Calabresi P, Gulino A. NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease. Neurosci Lett. 2008 Apr 4;434(3):241-6. doi: 10.1016/j.neulet.2007.09.056. Epub 2007 Oct 2. PMID: 18329171.

33. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):395-403. doi: 10.1089/ars.2005.7.395. PMID: 15706086.

34. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4328-32. doi: 10.1073/pnas.88.10.4328. PMID: 1903539; PMCID: PMC51652.
35. Maes M, Mihaylova I, Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett. 2007 Aug;28(4):456-62. PMID: 17693979.

36. Morris G, Maes M. Increased nuclear factor-κB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses. 2012 Nov;79(5):607-13. doi: 10.1016/j.mehy.2012.07.034. Epub 2012 Aug 27. PMID: 22951418.

37. Yang X, Li F, Liu Y, Li D, Li J. Study on the Correlation Between NF-κB and Central Fatigue. J Mol Neurosci. 2021 Feb 14. doi: 10.1007/s12031-021-01803-z. Epub ahead of print. PMID: 33586033.

38. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013 Aug;48(1):190-204. doi: 10.1007/s12035-013-8425-7. Epub 2013 Feb 26. PMID: 23436141; PMCID: PMC7091222.

39. Lucas K, Morris G, Anderson G, Maes M. The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue. CNS Neurol Disord Drug Targets. 2015;14(7):838-54. doi: 10.2174/1871527314666150317224645. PMID: 25801843.
40. Kruzel ML, Zimecki M, Actor JK. Lactoferrin in a Context of Inflammation-Induced Pathology. Front Immunol. 2017 Nov 6;8:1438. doi: 10.3389/fimmu.2017.01438. PMID: 29163511; PMCID: PMC5681489.

41. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res. 2011 Jan;21(1):71-85. doi: 10.1038/cr.2010.177. Epub 2010 Dec 21. PMID: 21173796; PMCID: PMC3193406.

42. Chen J, Liu XS. Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. J Leukoc Biol. 2009 Dec;86(6):1305-10. doi: 10.1189/jlb.0609406. Epub 2009 Sep 9. PMID: 19741156.

43. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008 May 1;180(9):5771-7. doi: 10.4049/jimmunol.180.9.5771. PMID: 18424693.

44. Mittal SK, Roche PA. Suppression of antigen presentation by IL-10. Curr Opin Immunol. 2015 Jun;34:22-7. doi: 10.1016/j.coi.2014.12.009. Epub 2015 Jan 16. PMID: 25597442; PMCID: PMC4444374.

45. Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett. 2007 Aug;28(4):477-83. PMID: 17693977
46. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res. 2012 Apr 30;196(2-3):243-9. doi: 10.1016/j.psychres.2011.09.029. Epub 2012 Feb 24. PMID: 22364930.

47. Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D. Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders. Cells. 2021 Jun 26;10(7):1603. doi: 10.3390/cells10071603. PMID: 34206739; PMCID: PMC8306609.

48. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y, Bienz M. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol. 2007 Jun;14(6):484-92. doi: 10.1038/nsmb1247. Epub 2007 May 27. PMID: 17529994.

49. Tietz S, Engelhardt B. Brain barriers: Crosstalk between complex tight junctions and adherens junctions. J Cell Biol. 2015 May 25;209(4):493-506. doi: 10.1083/jcb.201412147. PMID: 26008742; PMCID: PMC4442813.

50. Seth A, Sheth P, Elias BC, Rao R. Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer. J Biol Chem. 2007 Apr 13;282(15):11487-98. doi: 10.1074/jbc.M610597200. Epub 2007 Feb 12. PMID: 17298946.
51. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008 Mar;1778(3):660-9. doi: 10.1016/j.bbamem.2007.07.012. Epub 2007 Jul 27. PMID: 17854762; PMCID: PMC2682436.

52. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009 Jul;17(1):9-26. doi: 10.1016/j.devcel.2009.06.016. PMID: 19619488; PMCID: PMC2861485.

53. Rao R. Oxidative stress-induced disruption of epithelial and endothelial tight junctions. Front Biosci. 2008 May 1;13:7210-26. doi: 10.2741/3223. PMID: 18508729; PMCID: PMC6261932.

54. Silva-García O, Valdez-Alarcón JJ, Baizabal-Aguirre VM. Wnt/β-Catenin Signaling as a Molecular Target by Pathogenic Bacteria. Front Immunol. 2019 Sep 27;10:2135. doi: 10.3389/fimmu.2019.02135. PMID: 31611869; PMCID: PMC6776594.

55. Zhao H, Zhang J, Qian N, Wu S, Wu Y, Yao G. Oxidative stress caused by a dysregulated Wnt/β-catenin signalling pathway is involved in abnormal placenta formation in pregnant mice with chronic fatigue syndrome. Zygote. 2021 Apr;29(2):122-129. doi: 10.1017/S096719942000057X. Epub 2020 Oct 15. PMID: 33054899.

56. Funato Y, Michiue T, Asashima M, Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol. 2006 May;8(5):501-8. doi: 10.1038/ncb1405. Epub 2006 Apr 2. PMID: 16604061.
57. Karimaian A, Majidinia M, Bannazadeh Baghi H, Yousefi B. The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy. DNA Repair (Amst). 2017 Mar;51:14-19. doi: 10.1016/j.dnarep.2017.01.003. Epub 2017 Jan 11. PMID: 28108274.

58. Shin SY, Kim CG, Jho EH, Rho MS, Kim YS, Kim YH, Lee YH. Hydrogen peroxide negatively modulates Wnt signaling through downregulation of beta-catenin. Cancer Lett. 2004 Aug 30;212(2):225-31. doi: 10.1016/j.canlet.2004.03.003. PMID: 15279902.

59. Korswagen HC. Regulation of the Wnt/beta-catenin pathway by redox signaling. Dev Cell. 2006 Jun;10(6):687-8. doi: 10.1016/j.devcel.2006.05.007. PMID: 16740470.

60. Ma B, Hottiger MO. Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation. Front Immunol. 2016 Sep 22;7:378. doi: 10.3389/fimmu.2016.00378. PMID: 27713747; PMCID: PMC5031610.

61. Jridi I, Canté-Barrett K, Pike-Overzet K, Staal FJT. Inflammation and Wnt Signaling: Target for Immunomodulatory Therapy? Front Cell Dev Biol. 2021 Feb 4;8:615131. doi: 10.3389/fcell.2020.615131. PMID: 33614624; PMCID: PMC7890028.
62. Gustafson B, Smith U. Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem. 2006 Apr 7;281(14):9507-16. doi: 10.1074/jbc.M512077200. Epub 2006 Feb 7. PMID: 16464856.

63. Morris G, Puri BK, Walker AJ, Maes M, Carvalho AF, Walder K, Mazza C, Berk M. Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. Pharmacol Res. 2019 Oct;148:104450. doi: 10.1016/j.phrs.2019.104450. Epub 2019 Sep 8. PMID: 31509764.

64. Laksitorini MD, Yathindranath V, Xiong W, Hombach-Klonisch S, Miller DW. Modulation of Wnt/β-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells. Sci Rep. 2019 Dec 23;9(1):19718. doi: 10.1038/s41598-019-56075-w. PMID: 31873116; PMCID: PMC6928218.

65. Dickins EM, Salinas PC. Wnts in action: from synapse formation to synaptic maintenance. Front Cell Neurosci. 2013 Nov 5;7:162. doi: 10.3389/fncel.2013.00162. PMID: 24223536; PMCID: PMC3819050.

66. Marchetti B. Wnt/β-Catenin Signaling Pathway Governs a Full Program for Dopaminergic Neuron Survival, Neurorescue and Regeneration in the MPTP Mouse Model of Parkinson's Disease. Int J Mol Sci. 2018 Nov 24;19(12):3743. doi: 10.3390/ijms19123743. PMID: 30477246; PMCID: PMC6321180.
67. Manukjan N, Ahmed Z, Fulton D, Blankesteijn WM, Foulquier S. A Systematic Review of WNT Signaling in Endothelial Cell Oligodendrocyte Interactions: Potential Relevance to Cerebral Small Vessel Disease. Cells. 2020 Jun 25;9(6):1545. doi: 10.3390/cells9061545. PMID: 32630426; PMCID: PMC7349551.

68. Varela-Nallar L, Inestrosa NC. Wnt signaling in the regulation of adult hippocampal neurogenesis. Front Cell Neurosci. 2013 Jun 26;7:100. doi: 10.3389/fncel.2013.00100. PMID: 23805076; PMCID: PMC3693081.

69. Zhao Y, Yang Z. Effect of Wnt signaling pathway on pathogenesis and intervention of neuropathic pain. Exp Ther Med. 2018 Oct;16(4):3082-3088. doi: 10.3892/etm.2018.6512. Epub 2018 Jul 23. PMID: 30214530; PMCID: PMC6125982.

70. Zhao Y, Zhang L, Wang M, Yu J, Yang J, Liu A, Yao H, Liu X, Shen Y, Guo B, Wang Y, Wu S. Anxiety Specific Response and Contribution of Active Hippocampal Neural Stem Cells to Chronic Pain Through Wnt/β-Catenin Signaling in Mice. Front Mol Neurosci. 2018 Aug 24;11:296. doi: 10.3389/fnmol.2018.00296. PMID: 30197587; PMCID: PMC6117500.

71. Zhao C, Yu Y, Zhang Y, Shen J, Jiang L, Sheng G, Zhang W, Xu L, Jiang K, Mao S, Jiang P, Gao F. β-Catenin Controls the Electrophysiologic Properties of Skeletal Muscle Cells by Regulating the α2 Isoform of Na⁺/K⁺-ATPase. Front Neurosci. 2019 Aug 7;13:831. doi: 10.3389/fnins.2019.00831. PMID: 31440132; PMCID: PMC6693565.
72. Cisternas P, Henriquez JP, Brandon E, Inestrosa NC. Wnt signaling in skeletal muscle dynamics: myogenesis, neuromuscular synapse and fibrosis. Mol Neurobiol. 2014 Feb;49(1):574-89. doi: 10.1007/s12035-013-8540-5. Epub 2013 Sep 7. PMID: 24014138.

73. Moparthi L, Koch S. Wnt signaling in intestinal inflammation. Differentiation. 2019 Jul-Aug;108:24-32. doi: 10.1016/j.diff.2019.01.002. Epub 2019 Jan 24. PMID: 30718056.

74. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev. 2005 Apr 15;19(8):877-90. doi: 10.1101/gad.1295405. PMID: 15833914.

75. Flanagan DJ, Austin CR, Vincan E, Phesse TJ. Wnt Signalling in Gastrointestinal Epithelial Stem Cells. Genes (Basel). 2018 Mar 23;9(4):178. doi: 10.3390/genes9040178. PMID: 29570681; PMCID: PMC5924520.

76. Jeon MK, Klaus C, Kaemmerer E, Gassler N. Intestinal barrier: Molecular pathways and modifiers. World J Gastrointest Pathophysiol. 2013 Nov 15;4(4):94-9. doi: 10.4291/wjgp.v4.i4.94. PMID: 24244877; PMCID: PMC3829455.

77. Miao CG, Yang YY, He X, Li XF, Huang C, Huang Y, Zhang L, Lv XW, Jin Y, Li J. Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling. Cell Signal. 2013 Oct;25(10):2069-78. doi: 10.1016/j.cellsig.2013.04.002. Epub 2013 Apr 17. PMID: 23602936.
78. Cici D, Corrado A, Rotondo C, Cantatore FP. Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis. Int J Mol Sci. 2019 Nov 7;20(22):5552. doi: 10.3390/ijms20225552. PMID: 31703281; PMCID: PMC6888549.

79. Rogan MR, Patterson LL, Wang JY, McBride JW. Bacterial Manipulation of Wnt Signaling: A Host-Pathogen Tug-of-Wnt. Front Immunol. 2019 Oct 17;10:2390. doi: 10.3389/fimmu.2019.02390. PMID: 31681283; PMCID: PMC6811524.

80. Ljungberg JK, Kling JC, Tran TT, Blumenthal A. Functions of the WNT Signaling Network in Shaping Host Responses to Infection. Front Immunol. 2019 Nov 8;10:2521. doi: 10.3389/fimmu.2019.02521. PMID: 31781093; PMCID: PMC6857519.

81. Maes M, Twisk FN. Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS. Neuro Endocrinol Lett. 2009;30(6):677-93. PMID: 20038921.

82. Jason LA, Corradi K, Gress S, Williams S, Torres-Harding S. Causes of death among patients with chronic fatigue syndrome. Health Care Women Int. 2006 Aug;27(7):615-26. doi: 10.1080/07399330600803766. PMID: 16844674.
**Table 1.** PANTHER molecular function and components terms associated with chronic fatigue spectrum disorders

| PANTHER molecular functions                  | total  | expected | hits  | P            | pFDR     |
|---------------------------------------------|--------|----------|-------|--------------|----------|
| Protein binding                             | 9580   | 334      | 461   | 9.74E-33     | 1.89E-30 |
| Peroxidase activity                         | 31     | 1.08     | 21    | 5.38E-24     | 5.22E-22 |
| Oxidoreductase activity                     | 590    | 20.6     | 75    | 7.24E-23     | 4.68E-21 |
| RNA binding                                 | 1510   | 52.6     | 107   | 4.94E-13     | 2.39E-11 |
| Nuclear receptor activity                   | 45     | 1.57     | 14    | 2.04E-10     | 7.93E-09 |
| Signaling receptor binding                  | 413    | 14.4     | 38    | 5.05E-08     | 1.63E-06 |
| Double-stranded DNA binding                 | 128    | 4.46     | 18    | 4.71E-07     | 1.30E-05 |
| Antioxidant activity                        | 26     | 0.906    | 8     | 1.86E-06     | 4.50E-05 |

| PANTHER cellular components                 | total  | expected | hits  | P            | pFDR     |
|---------------------------------------------|--------|----------|-------|--------------|----------|
| Cytosol                                     | 5030   | 157      | 330   | 1.11E-53     | 5.88E-52 |
| Protein-containing complex                  | 656    | 20.6     | 85    | 1.34E-29     | 3.54E-28 |
| Cytoplasm                                   | 6540   | 205      | 334   | 3.10E-29     | 5.48E-28 |
| Nucleus                                     | 6480   | 203      | 309   | 2.33E-20     | 3.08E-19 |
| Mitochondrion                               | 1510   | 47.2     | 94    | 6.79E-11     | 7.19E-10 |
| Peroxisome                                  | 119    | 3.73     | 21    | 1.19E-10     | 1.05E-09 |
| Protein-DNA complex                         | 44     | 1.38     | 12    | 6.72E-09     | 5.09E-08 |

FDR: false discovery rate.
Table 2. Results of Molecular Complex Detection (MCODE) analysis performed on the differently expressed proteins (DEPs) of chronic fatigue spectrum disorders

| MCODE Components | GO ID       | Biological term                                | Log10 (p) |
|------------------|-------------|-----------------------------------------------|-----------|
| All DEPs, MCODE_ALL | GO:0098869  | Cellular oxidant detoxification                | -33.0     |
|                   | GO:1990748  | Cellular detoxification                        | -31.5     |
|                   | GO:0097237  | Cellular response to toxic substance           | -30.8     |
| All DEPs, MCODE1 | R-HSA-449147| Signaling by Interleukins                      | -31.9     |
|                   | R-HSA-6783783 | Interleukin-10 signaling                   | -30.0     |
|                   | GO:0032496  | Response to lipopolysaccharide                 | -29.7     |
| All DEPs, MCODE2 | Same as MCODE_ALL |                                      |           |
| All DEPs, MCODE3 | R-HSA-140179| Amine Oxidase reactions                        | -9.0      |
|                   | GO:0042743  | hydrogen peroxide metabolic process            | -7.2      |
|                   | M31         | PID BETA CATENIN DEG PATHWAY                  | -6.7      |
| All DEPs, MCODE4 | R-HSA-9033241| Peroxisomal protein import                    | -16.6     |
|                   | R-HSA-9609507 | Protein localization                       | -13.6     |
|                   | GO:0046395  | Carboxylic acid catabolic process              | -10.2     |
Table 3. GO biological process terms, InterPro domains and KEGG pathways associated with chronic fatigue spectrum disorders

| Path ID     | Enrichment GO biological process                                                                 | Observed | background | Strength | pFDR    |
|-------------|---------------------------------------------------------------------------------------------------|----------|------------|----------|---------|
| GO:0016491  | Oxidoreductase activity                                                                           | 49       | 726        | 0.95     | 1.29E-28|
| GO:0016209  | Antioxidant activity                                                                             | 22       | 74         | 1.6      | 1.35E-23|
| GO:0004601  | Peroxidase activity                                                                              | 17       | 41         | 1.74     | 6.98E-20|
| GO:0008013  | Beta-catenin binding                                                                             | 16       | 86         | 1.39     | 4.55E-14|
| GO:0005515  | Protein binding                                                                                  | 102      | 7026       | 0.29     | 1.96E-13|
| GO:0042802  | Identical protein binding                                                                        | 51       | 1896       | 0.55     | 1.96E-13|
| GO:0016641  | Oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor                 | 10       | 16         | 1.92     | 1.22E-12|
| GO:0050660  | Flavin adenine dinucleotide binding                                                               | 14       | 82         | 1.36     | 7.21E-12|
| GO:0020037  | Heme binding                                                                                     | 15       | 134        | 1.17     | 1.75E-10|
| GO:0003824  | Catalytic activity                                                                               | 80       | 5486       | 0.29     | 8.35E-09|
| GO:0004602  | Glutathione peroxidase activity                                                                  | 8        | 20         | 1.73     | 8.35E-09|

| Path ID     | Enrichment InterPro                                                                         | Observed | background | Strength | pFDR    |
|-------------|------------------------------------------------------------------------------------------------|----------|------------|----------|---------|
| IPR010255   | Haem peroxidase superfamily                                                                   | 8        | 10         | 2.03     | 9.50E-09|
| IPR019791   | Haem peroxidase, animal-type                                                                  | 8        | 10         | 2.03     | 9.50E-09|
| IPR037120   | Haem peroxidase domain superfamily, animal type                                               | 8        | 10         | 2.03     | 9.50E-09|
| IPR000889   | Glutathione peroxidase                                                                         | 7        | 8          | 2.07     | 4.98E-08|
| IPR029760   | Glutathione peroxidase conserved site                                                          | 7        | 8          | 2.07     | 4.98E-08|
| IPR002937   | Amine oxidase                                                                                  | 7        | 10         | 1.97     | 9.91E-08|
| IPR036188   | FAD/NAD(P)-binding domain superfamily                                                         | 10       | 56         | 1.38     | 2.41E-07|
| IPR029759   | Glutathione peroxidase active site                                                             | 6        | 7          | 2.06     | 9.34E-07|

| Path ID     | Enrichment KEGG                                                                             | Observed | background | Strength | pFDR    |
|-------------|------------------------------------------------------------------------------------------------|----------|------------|----------|---------|
| hsa04310    | Wnt signaling pathway                                                                         | 18       | 154        | 1.19     | 3.25E-13|
| hsa05152    | Tuberculosis                                                                                  | 18       | 168        | 1.15     | 6.53E-13|
| hsa04064    | NF-kappa B signaling pathway                                                                  | 15       | 101        | 1.3      | 1.30E-12|
| hsa00380    | Tryptophan metabolism                                                                         | 11       | 41         | 1.55     | 1.43E-11|
| ID    | Description                              | Count | Total | FDR   | p-value  |
|-------|------------------------------------------|-------|-------|-------|----------|
| hsa04146 | Peroxisome                             | 13    | 79    | 1.34  | 1.43E-11 |
| hsa05142 | Chagas disease                         | 14    | 99    | 1.27  | 1.43E-11 |
| hsa05163 | Human cytomegalovirus infection        | 18    | 218   | 1.04  | 1.43E-11 |
| hsa01100 | Metabolic pathways                      | 40    | 1447  | 0.57  | 2.64E-11 |
| hsa04520 | Adherens junction                       | 12    | 67    | 1.38  | 3.16E-11 |
| hsa05010 | Alzheimer disease                       | 21    | 355   | 0.9   | 3.21E-11 |
Table 4. Results of inBio Discover annotation analysis with the top-10 and custom-made DOID annotations associated with chronic fatigue spectrum disorders

| DOID ID  | Disease                                | Size | Overlap   | Enrichment | p-value  |
|----------|----------------------------------------|------|-----------|------------|----------|
| DOID:77  | Gastrointestinal system disease        | 2.3k | 133/419   | 2.81       | 6.1E-30  |
| DOID:5295| Intestinal disease                     | 1.0k | 82/419    | 3.86       | 1.3E-26  |
| DOID:0050589| Inflammatory bowel disease         | 306  | 46/419    | 7.18       | 4.4E-26  |
| DOID:00600180| Colitis                              | 237  | 41/419    | 8.26       | 9.1E-26  |
| DOID:2914| Immune system disease                 | 1.9k | 111/419   | 2.79       | 3.1E-24  |
| DOID:612 | Primary immunodeficiency disease      | 1.3k | 87/419    | 3.12       | 6.4E-22  |
| DOID:7   | Disease of anatomical entity          | 7.3k | 248/419   | 1.62       | 1.5E-21  |
| DOID:417 | Autoimmune disease                    | 1.1k | 75/419    | 3.36       | 1.2E-20  |
| DOID:0050686 | Organ system cancer                  | 3.9k | 161/419   | 1.99       | 2.8E-20  |
| DOID:162 | Cancer                                 | 4.2k | 168/419   | 1.93       | 8.0E-20  |

| DOID ID  | Selected annotations                  | Size | Overlap   | Enrichment | p-value  |
|----------|---------------------------------------|------|-----------|------------|----------|
| DOID:0097237| Cellular response to a toxic substance | 77   | 23/419    | 14.26      | 1.2E-20  |
| DOID:0042221| Response to chemical                  | 2.4k | 111/419   | 2.20       | 2.5E-16  |
| DOID:0040085| Bacterial sepsis                      | 13   | 9/419     | 33.05      | 4.7E-13  |
| DOID:934 | Viral infectious disease              | 664  | 43/419    | 3.23       | 4.3E-12  |
| DOID:104 | Bacterial infectious disease          | 268  | 27/419    | 4.81       | 1.7E-11  |
| DOID:0042742| Response to bacterium                | 251  | 23/419    | 4.37       | 3.6E-9   |
| DOID:0071219 | Cellular response to a molecule of bacterial origin | 80 | 13/419 | 7.76 | 1.1E-8 |
|--------------|---------------------------------------------------|----|--------|------|--------|
| DOID:0050338 | Primary bacterial infectious disease               | 219| 20/419 | 4.36 | 4.08E-8|
| GO:0002237   | Response to a molecule of bacterial origin         | 107| 13/419 | 5.80 | 3.8E-7 |
| DOID:0050339 | Commensal bacterial infectious disease             | 46 | 9/419  | 9.34 | 4.0E-7 |
Figure 1. First order protein-protein interaction network of chronic fatigue spectrum disorders. MCL cluster analysis found two subnetworks: 1) a first immune subnetwork (red color) was centered around NFKB1, TNF, IL6, IL10, IL1, TLR4, etc., and 2) a second Wnt/catenin subnetwork (green nodes) centered around CTNNB1.
**Figure 2.** First order protein network of chronic fatigue spectrum disorders. MCL cluster analysis found two major subnetworks: 1) a first immune, oxidative and nitrosative subnetwork (IO&NS; red color) was centered around NOS2, NFkB1, IL10, etc, and 2) a second Wnt/catenin subnetwork (yellow nodes) was centered around CTNNB1. The tryptophan catabolite pathway (KYNU and KMO) and opioid (OPRK1 and OPRM1) genes appear to be spin-offs of the IO&NS subnetworks.
Figure 3. Results of OmicsNet analysis which included all genes of the network with integration of the metabolics and NFKB1. Metabolics are shown in yellow color, and NFKB1 (as transcriptional factor) in green. 3HK: 3-hydroxy-kynurenine; NO: nitric oxide; EPA: eicosapentaenoic acid
Figure 4. Heatmap of enriched ontology clusters showing the top-20 functions that were overexpressed in the network of patients with chronic fatigue spectrum disorders (accumulative hypergeometric p-values)
Figure 5. Heatmap (top-10) of enriched KEGG terms accumulated in the differently expressed proteins of the enlarged MultiOmics network of chronic fatigue spectrum disorders.
Figure 6. Heatmap (top-10) of enriched PANTHER terms accumulated in the differently expressed proteins of the enlarged MultiOmics network of chronic fatigue spectrum disorders
ELECTRONIC SUPPLEMENTARY FILE (ESF) 1

Aberrations in the cross-talks among redox, nuclear factor-κB and Wnt/catenin pathway signaling underpin Myalgic Encephalomyelitis and chronic fatigue syndrome: a review and new hypothesis based on results of network, enrichment and annotation analyses.

Michael Maes, M.D., Ph.D. a,b,c, Marta Kubera, d Magdalena Kotańska, Ph.D e

a Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

b Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria

c IMPACT Strategic Research Center, Deakin University, Geelong, Australia

d Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Crakow, Poland

e Department of Pharmacological Screening, Jagiellonian University, Medical College, Medyczna 9, PL 30-688 Cracow, Poland
Enrichment analysis in all DEPs of CFAS-D.

**ESF 1, Table 1** displays the results of MCODE analysis employing KEGG, WikiPaths, GO biological and molecular, REACTOME and PANTHER performed on the first-order network built using all seed genes. We observed three significant molecular complexes: the first represents IL10 signaling and signaling by interleukins; the second reflects canonical Wnt signaling and cell-cell signaling by Wnt; and the third represents TCF-dependent signaling in response to Wnt and Wnt signaling.

**ESF 2, Figure 1** shows the enriched ontology term clusters in the first order network build using all genes (the network is constructed and visualized using MetaScape and Cytoscape, v3.1.2). This figure shows that the immune and Wnt subnetworks are strongly intertwined as well as the MAPK cascade and that these pathways are interconnected with multicellular organismal homeostasis.

**ESF 2, Figure 2** shows the top-20 terms which were over-represented in the first order network built using all genes. This bar graph shows that besides cytokine (especially IL10) and Wnt signaling also positive regulation of the MAPK cascade is a significant path.

**ESF 1, Table 2** shows the GO biological process and WikiPathways associated with CFAS-D. The top GO annotation terms were: the cell surface receptor signaling pathway, positive regulation of response to stimulus, and positive regulation of cell communication. The top WikiPathway names associated with CFAS-D were Alzheimer’s disease, TNF-related weak inducer of apoptosis (TWEAK) signaling pathway, LTF danger signal response pathway, TLR signaling pathway, and miRNAs involvement in the immune response in sepsis.
Enrichment analysis on the immune subnetwork genes of CFASD.

**ESF 2, Figure 3** shows the enriched ontology term clusters in the immune subnetwork of CFAS-D and that cytokine (in particular IL10, but also IL4 and IL13) signaling, a response to LPS or an external stimulus were strongly interacting pathways.

**ESF 2, Figure 4** shows the top WikiPaths which were over-represented in the immune subnetwork, namely the LTF danger signal response pathway and the TLR pathway. **ESF 2, Figure 5** shows a bar graph with the top-10 BioCarta terms which are over-represented in the immune subnetwork, namely NFKB pathway, anti-inflammatory IL10, IL1R, TNFR1 and ceramide signaling. **ESF 2, Figure 6** shows the top-10 KEGG annotations including Chagas disease, tuberculosis, CMV infection, toxoplasmosis, and viral protein interactions with cytokine and cytokine receptor.

Enrichment analysis on the Wnt subnetwork genes of CFAS-D.

**ESF 2, Figure 7 and 8** shows the enriched ontology term clusters in the Wnt subnetwork of CFAS-D. Besides Wnt/catenin-associated paths, these also include diseases of signal transduction, signaling by Wnt in cancer, PID PS1 pathway and cell-junction organization. **ESF 2, Figure 9** shows the WikiPathways which were statistically over-represented in the Wnt/catenin subnetwork, including involvement of this pathway in colorectal cancer, leukemia, endometrial and breast cancer, etc. The bar graph shown in **ESF 2, Figure 10** shows the top-10 InterPro domains which were enriched in the Wnt subnetwork, including the cadherin prodomain and cytoplasmic domain, and the DIX domain. **ESF 2, Figure 11** shows a bar graph with top-10 enriched GO cellular components, including
the catenin complex and adherens and cell-cell junctions. TTRUST enrichment analysis showed that NFKB1 (pFDR=2.911E-25) and RELA (pFDR=1.014E-22) were the two most important transcriptional factors in this network.

**Annotation analyses and functional categorization of the PPI network and selected genes**

**ESF 2, Figures 12 and 13** depict the hierarchical structure of GO terms and the hubs and master regulatory transcription factor (ESF 2, Figure 12), downregulated seed genes (**ESF 2, Figure 13A**), seed genes of the Wnt/catenin pathway subnetwork (**ESF 2, Figure 13B**), and the major hotspots in the STRING enlarged networks (**ESF 2, Figure 13C**). Thus, ESF 2, Figure 12 shows that the GO functions which are regulated by NFKB1, CTNNB1, TNF and IL6. ESF 2, Figure 13A shows that the downregulated genes are associated with cellular oxidant detoxification and detoxification in general. ESF 2, Figure 13B shows that the seed genes of the Wnt subnetwork are associated with synapse organization and cell-cell signaling, whereas the major hotspots of the enlarged network (ESF 2, Figure 13C) are associated with a variety of processes including smooth muscle cell proliferation, regulation of DNA metabolic and apoptotic processes, and response to lipids, steroid hormones.
**ESF 1, Table 1.** Results of Molecular Complex Detection (MCODE) analysis performed on the differently expressed proteins (DEPs) of chronic fatigue spectrum disorders.

| MCODE Components           | GO ID          | Biological term                              | Log10 (p) |
|----------------------------|----------------|----------------------------------------------|-----------|
| All DEPs, MCODE1          | R-HSA-6783783  | Interleukin-10 signaling                      | -32.5     |
|                            | R-HSA-449147   | Signaling by Interleukins                     | -31.9     |
|                            | R-HSA-1280215  | Cytokine signaling in immune system           | -30.2     |
| All DEPs, MCODE2          | GO:0060070     | Canonical Wnt signaling pathway               | -12.4     |
|                            | GO:0016055     | Wnt signaling pathway                         | -10.9     |
|                            | GO:0198738     | Cell-cell signaling by Wnt                    | -10.9     |
| All DEPs, MCODE3          | R-HSA-201681   | TCF dependent signaling in response to Wnt    | -5.3      |
|                            | GO:0060070     | Canonical Wnt signaling pathway               | -4.9      |
|                            | R-HSA-195721   | Signaling by WNT                              | -4.8      |
**ESF 1, Table 2.** Go Biological Process and WikiPathway terms associated with the network of chronic fatigue spectrum disorders (CFAS-D).

| Path ID   | GO biological process names associated with CFAS-D                                                                 | Observed | background | Strength | pFDR    |
|-----------|------------------------------------------------------------------------------------------------------------------------|----------|------------|----------|---------|
| GO:0007166| Cell surface receptor signaling pathway                                                                                 | 63       | 2325       | 0.77     | 1.23E-32|
| GO:0048584| Positive regulation of response to stimulus                                                                           | 60       | 2257       | 0.76     | 4.05E-30|
| GO:0048583| Regulation of response to stimulus                                                                                     | 72       | 4114       | 0.58     | 3.43E-28|
| GO:0010647| Positive regulation of cell communication                                                                               | 52       | 1823       | 0.79     | 3.87E-26|
| GO:0023056| Positive regulation of signaling                                                                                       | 52       | 1831       | 0.79     | 3.87E-26|
| GO:0009967| Positive regulation of signal transduction                                                                             | 50       | 1654       | 0.81     | 4.58E-26|
| GO:0042221| Response to chemical                                                                                                     | 71       | 4333       | 0.55     | 5.73E-26|
| GO:0009893| Positive regulation of metabolic process                                                                             | 68       | 3893       | 0.57     | 9.50E-26|
| GO:0070887| Cellular response to chemical stimulus                                                                                  | 61       | 2919       | 0.65     | 1.05E-25|
| GO:0048522| positive regulation of cellular process                                                                               | 77       | 5579       | 0.47     | 2.79E-25|

| Path ID   | WikiPathway names associated with CFAS-D                                                                                | Observed | background | Strength | pFDR    |
|-----------|------------------------------------------------------------------------------------------------------------------------|----------|------------|----------|---------|
| WP5124    | Alzheimers disease                                                                                                       | 20       | 255        | 1.23     | 1.94E-15|
| WP2036    | TNF-related weak inducer of apoptosis (TWEAK) signaling pathway                                                         | 11       | 42         | 1.75     | 4.25E-13|
| WP5039    | SARS-CoV-2 innate immunity evasion and cell-specific immune response                                                     | 12       | 66         | 1.59     | 6.76E-13|
| WP4478    | LTF danger signal response pathway                                                                                      | 9        | 19         | 2.01     | 1.46E-12|
| WP75      | Toll-like receptor signaling pathway                                                                                    | 13       | 103        | 1.43     | 2.01E-12|
| WP4329    | miRNAs involvement in the immune response in sepsis                                                                     | 10       | 37         | 1.76     | 3.05E-12|
| WP4155    | Endometrial cancer                                                                                                       | 11       | 63         | 1.57     | 8.07E-12|
| WP3658    | Wnt/beta-catenin signaling pathway in leukemia                                                                           | 9        | 26         | 1.87     | 8.09E-12|
| WP251     | TNF-alpha signaling pathway                                                                                                | 12       | 92         | 1.45     | 9.77E-12|
| WP4258    | IncRNA in canonical Wnt signaling and colorectal cancer                                                                   | 12       | 93         | 1.44     | 9.99E-12|
ESF 1. References

Asad HN, Al-Hakeim H, Moustafa SR, Maes M. A causal-pathway phenotype of chronic fatigue syndrome due to hemodialysis. Submitted.

Al-Hakeim H, Moustafa SR, Maes M. Biomarkers of chronic fatigue and depression in patients with rheumatoid arthritis: a nomothetic network analysis. Submitted.

Al-Jassas H, Al-Hakeim H, Maes M. Intersections between Pneumonia, Lowered Oxygen Saturation Percentage and Immune Activation Mediate Depression, Anxiety and Chronic Fatigue Syndrome-like Symptoms due to COVID-19: A Nomothetic Network Approach. Preprints 2021, 2021060362 (doi: 10.20944/preprints202106.0362.v1).

Maes M, Kubera M, Stoyanova K, Leunis JC. The reification of the clinical diagnosis of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) as an immune and oxidative stress disorder: construction of a data-driven nomothetic network and exposure of ME/CFS subgroups. Curr Top Med Chem. 2021 Jul 27. doi:10.2174/1568026621666210727170147. Epub ahead of print. PMID: 34315375.

Mousa RF, Al-Hakeim HK, Alhaideri A, Maes M. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates. Metab Brain Dis. 2021 Jan;36(1):169-183. doi: 10.1007/s11011-020-00619-x. Epub 2020 Sep 23. PMID:32965599.

Almulla AF, Al-Hakeim HK, Abed MS, Carvalho AF, Maes M. Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways. Schizophr Res. 2020 Aug;222:342-353. doi: 10.1016/j.schres.2020.05.003. Epub 2020 May 26. PMID: 32467068.

Al-Hakeim HK, Al-Issa AAR, Maes M. Serum agrin and talin are increased in major depression while agrin and creatine phosphokinase are associated with chronic fatigue and fibromyalgia symptoms in depression. Metab Brain Dis. 2020 Jan;35(1):225-235. doi: 10.1007/s11011-019-00506-0. Epub 2019 Nov 16. PMID:31734845.
Kanchanatawan B, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Maes M. In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related To Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study. Neurotox Res. 2018 Apr;33(3):641-655. doi: 10.1007/s12640-018-9868-4. Epub 2018 Jan 29. PMID: 29380275.

Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Ivanova R, Maes M. Physiosomatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metab Brain Dis. 2017 Aug;32(4):1003-1016. doi: 10.1007/s11011-017-9982-7. Epub 2017 Mar 3. PMID: 28258445.

Maes M, Bosmans E, Kubera M. Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers. Neuro Endocrinol Lett. 2015;36(5):439-46. PMID: 26707044.

Maes M. A new case definition of Neuro-Inflammatory and Oxidative Fatigue (NIOF), a neuroprogressive disorder, formerly known as chronic fatigue syndrome or Myalgic Encephalomyelitis: results of multivariate pattern recognition methods and external validation by neuro-immune biomarkers. Neuro Endocrinol Lett. 2015;36(4):320-9. PMID: 26454487.

Maes M, Leunis JC, Geffard M, Berk M. Evidence for the existence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with and without abdominal discomfort (irritable bowel) syndrome. Neuro Endocrinol Lett. 2014;35(6):445-53. PMID: 25433843.

Morris G, Maes M. Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Curr Neuropharmacol. 2014 Mar;12(2):168-85. doi: 10.2174/1570159X11666131120224653. PMID: 24669210; PMCID: PMC3964747.

Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord. 2013 Sep 5;150(2):223-30. doi: 10.1016/j.jad.2013.03.029. Epub 2013 May 10. PMID: 23664637.
Maes M, Twisk FN, Ringel K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom. 2012;81(5):286-95. doi: 10.1159/000336803. Epub 2012 Jul 20. PMID: 22832503.

Maes M, Twisk FN, Kubera M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012 Feb;136(3):933-9. doi: 10.1016/j.jad.2011.09.004. Epub 2011 Oct 4. PMID: 21975140.

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett. 2011;32(2):133-40. PMID: 21552194.

Maes M, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit. 2011 Apr;17(4):SC11-5. doi: 10.12659/msm.881699. PMID: 21455120; PMCID: PMC3539515.

Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett. 2009;30(4):470-6. PMID: 20010505.

Maes M, Mihaylova I, Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett. 2007 Aug;28(4):456-62. PMID: 17693979.

Maes M, Mihaylova I, Kubera M, Bosmans E. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett. 2007 Aug;28(4):463-9. PMID: 17693978.
Mihaylova I, DeRuyter M, Rummens JL, Bosmans E, Maes M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett. 2007 Aug;28(4):477-83. PMID: 17693977.

Maes M, Mihaylova I, Leunis JC. In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett. 2005 Dec;26(6):745-51. PMID: 16380690.

Maes M, Mihaylova I, De Ruyter M. Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord. 2006 Feb;90(2-3):141-7. doi: 10.1016/j.jad.2005.11.002. Epub 2005 Dec 9. PMID: 16338007.

Maes M, Mihaylova I, De Ruyter M. Decreased dehydroepiandrosterone sulfate but normal insulin-like growth factor in chronic fatigue syndrome (CFS): relevance for the inflammatory response in CFS. Neuro Endocrinol Lett. 2005 Oct;26(5):487-92. PMID: 16264414.
ELECTRONIC SUPPLEMENTARY FILE (ESF) 2

Aberrations in the cross-talks among redox, nuclear factor-κB and Wnt/catenin pathway signaling underpin Myalgic Encephalomyelitis and chronic fatigue syndrome: a review and new hypothesis based on results of network, enrichment and annotation analyses.

Michael Maes, M.D., Ph.D. a,b,c, Marta Kubera, d Magdalena Kotańska, Ph.D e

a Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
b Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria
c IMPACT Strategic Research Center, Deakin University, Geelong, Australia
d Laboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Crakow, Poland
e Department of Pharmacological Screening, Jagiellonian University, Medical College, Medyczna 9, PL 30-688 Cracow, Poland
**ESF 2, Figure 1.** Enriched ontology term clusters in the chronic fatigue spectrum disorders network. Terms are represented by a circle node, with the colors representing cluster identity and their size reflecting the number of input genes. One term is used to describe the clusters (colored labels). The thickness of the (bundled) edges linking the terms reflects the similarity score (threshold is > 0.3). The network is constructed and visualized using MetaScape and Cytoscape (v3.1.2)
**ESF 2, Figure 2.** Heatmap of enriched ontology clusters showing the top-20 functions that were overexpressed in the expanded network of patients with chronic fatigue spectrum disorders (accumulative hypergeometric p-values)
**ESF 2, Figure 3.** Enriched ontology term clusters in the immune subnetwork of chronic fatigue spectrum disorders.

Terms are represented by a circle node, with the colors representing cluster identity and their size reflecting the number of input genes. One term is used to describe the clusters (colored labels). The thickness of the (bundled) edges linking the terms reflects the similarity score (threshold is > 0.3). The network is constructed and visualized using MetaScape and Cytoscape (v3.1.2)
| Pathway Description                                                                 | p-value  |
|------------------------------------------------------------------------------------|----------|
| LTF danger signal response pathway WP4478                                           | 8.05e-19 |
| Toll-like Receptor Signaling Pathway WP75                                            | 2.72e-18 |
| miRNAs involvement in the immune response in sepsis WP4329                          | 7.31e-18 |
| Regulation of toll-like receptor signaling pathway WP1449                           | 1.53e-16 |
| Photodynamic therapy-induced NF-kB survival signaling WP3617                        | 5.94e-16 |
| Selenium Micronutrient Network WP15                                                 | 1.68e-15 |
| Fibrin Complement Receptor 3 Signaling Pathway WP4136                               | 2.91e-15 |
| TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036              | 3.69e-15 |
| SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039         | 4.15e-15 |
| Folate Metabolism WP176                                                             | 6.65e-15 |

**ESF 2, Figure 4.** Heatmap (top-10) of the enriched WikiPathway terms accumulated in the differently expressed proteins of the immune subnetwork of chronic fatigue spectrum disorders.
**ESF 2, Figure 5.** Heatmap (top-10) of the BioCarta terms accumulated in the differently expressed proteins of the expanded immune subnetwork of chronic fatigue spectrum disorders.
**Figure 6.** Heatmap (top-10) of the KEGG pathways accumulated in the differently expressed proteins of the expanded immune subnetwork of chronic fatigue spectrum disorders.
**ESF 2, Figure 7.** Enriched ontology term clusters in the Wnt/catenin subnetwork of chronic fatigue spectrum disorders. Terms are represented by a circle node, with the colors representing cluster identity and their size reflecting the number of input genes. One term is used to describe the clusters (colored labels). The thickness of the (bundled) edges linking the terms reflects the similarity score (threshold is > 0.3). The network is constructed and visualized using MetaScape and Cytoscape (v3.1.2).
**ESF 2, Figure 8.** Heatmap of enriched ontology clusters showing the top-20 functions that were overexpressed in the Wnt/catenin subnetwork of patients with chronic fatigue spectrum disorders (accumulative hypergeometric p-values)
**ESF 2, Figure 9.** Heatmap (top-10) of the WikiPathways accumulated in the differently expressed proteins of the expanded Wnt subnetwork of chronic fatigue spectrum disorders.
**ESF 2, Figure 10.** Heatmap (top-10) of enriched InterPro domain terms accumulated in the differently expressed proteins of the Wnt/catenin subnetwork of chronic fatigue spectrum disorders
ESF 2, Figure 11. Heatmap (top-10) of enriched cellular component terms accumulated in the differently expressed proteins of the Wnt/catenin subnetwork of chronic fatigue spectrum disorders.
ESF 2, Figure 12. Results of GOnet annotation visualization in chronic fatigue spectrum disorders depicting the hierarchical structure of GO terms and the hubs and master regulatory transcription factor
ESF 2, Figure 13. Results of GOnet annotation visualization in chronic fatigue spectrum disorders depicting the hierarchical structure of GO terms and A: downregulated seed genes; B: seed genes of the Wnt/catenin pathways; and C: the hotspots in STRING enlarged networks.
ESF 2, Figure 14. An extended network constructed with inBio Discover showing the top Disease Ontology (DOID) annotations of chronic fatigue spectrum disorders
